Capecitabine USP


Cabanib-20: Each capsule contains Cabozantinib 20mg as Cabozantinib (S) Malate INN

Cabanib-60: Each capsule contains Cabozantinib 60mg as Cabozantinib (S) Malate INN

Indications: Cabozantinib is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).

Dosage and Administration: The recommended daily dose of Cabozantinib is 140 mg once daily without food until disease progression or unacceptable toxicity. Patients should not be instructed to eat for at least 2 hours before and at least 1 hour after taking Cabozantinib. Cabozantinib capsules should be swallowed whole and it should be opened. A missed dose should not be taken within 12 hours of the next dose. Foods (e.g., grapefruit, grapefruit juice) or nutritional supplements should not be taken that are known to inhibit cytochrome P450 while taking Cabozantinib.

Use in Pregnancy and Lactation: It can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. Pregnant women or women of childbearing potential should be advised of the potential hazard to a fetus. The estimated background risk of major birth defect and miscarriage for the indicated population is unknown. Lactation: There is no information regarding the presence of Cabozantinib or its metabolites in human milk, or their effects on the breastfed infant, or milk production. Because of the potential for serious adverse reactions in a breastfed infant from Cabozantinib, a lactating woman should not to be advised breastfeed during treatment with Cabozantinib and for 4 months after the final dose.


Cabanib-20: Each box contains 30 capsules in a blister pack.

Cabanib-60: Each box contains 30 capsules in a blister pack.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.